基于达雷妥尤单抗治疗获得性C1抑制物缺乏所致单克隆丙种球蛋白病相关血管性水肿。
Daratumumab-based treatment of monoclonal gammopathy-associated angioedema due to acquired C1-inhibitor deficiency.
作者信息
Petersen Remy S, Fijen Lauré M, Franssen Laurens E, Vos Josephine M I, Cohn Danny M
机构信息
Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Department of Hematology, Jeroen Bosch Hospital, Den Bosch, The Netherlands.
出版信息
J Allergy Clin Immunol Glob. 2024 Aug 5;3(4):100322. doi: 10.1016/j.jacig.2024.100322. eCollection 2024 Nov.
Abstract
Daratumumab-based treatment could control severe, treatment-refractory, life-threatening angioedema due to acquired C1-inhibitor deficiency associated with monoclonal gammopathy.
摘要
基于达雷妥尤单抗的治疗可控制因与单克隆丙种球蛋白病相关的获得性C1抑制物缺乏所致的严重、难治性、危及生命的血管性水肿。
Zotero 插件